Atezolizumab + Placebo + Doxorubicin + Cyclophosphamide + Paclitaxel + Trastuzumab + Pertuzumab + Trastuzumab Emtansine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Jan 11, 2019 → Aug 24, 2023
NCT ID
NCT03726879About Atezolizumab + Placebo + Doxorubicin + Cyclophosphamide + Paclitaxel + Trastuzumab + Pertuzumab + Trastuzumab Emtansine
Atezolizumab + Placebo + Doxorubicin + Cyclophosphamide + Paclitaxel + Trastuzumab + Pertuzumab + Trastuzumab Emtansine is a phase 3 stage product being developed by Chugai Pharmaceutical for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03726879. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03726879 | Phase 3 | Completed |
Competing Products
20 competing products in Breast Cancer